Latest Breaking News On - Division of neuromuscular diseases - Page 1 : vimarsana.com

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy s Disease)

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy s Disease)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGreat britainChristopher grunseichAlexandra macleanTahseen mozaffarJaclyn jaffeDrug administration or european medicines agencyNational institute of neurological disordersAnnji pharmaceutical coCompany phaseFortress biotech incUniversity of californiaLasker clinical research scholarLaboratory medicineEuropean union

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAlexandra macleanChristopher grunseichJaclyn jaffeTahseen mozaffarNeuromuscular centerLasker clinical research scholarDrug development researchNational institute of neurological disordersFortress biotech incAvenue therapeutics incLaboratory medicineAmerican society for experimental neurotherapeuticsDivision of neuromuscular diseasesUniversity of californiaChief executive officer

Amicus Therapeutics Announces FDA Approval and Launch of

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults.

United kingdomUnited statesTahseen mozaffarAndrew faughnanPriya kishnaniJohnf crowleyBradley campbellDiana mooreMaltase deficiency associationHead of global corporate communicationsAmicus therapeutics incExchange commissionDepartment of neurologyDrug administrationDivision of neuromuscular diseasesEuropean union

Amicus Therapeutics, Inc : Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Amicus Therapeutics, Inc : Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBaden wübergBradley campbellTahseen mozaffarPriya kishnaniJohnf crowleyDiana mooreAndrew faughnanDivision of neuromuscular diseasesDepartment of neurologyTeam amicuSchool of medicineHead of global corporate communicationsMaltase deficiency associationEuropean union

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ + Opfolda™ Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference.

United statesUnited kingdomAndrew faughnanPriya kishnaniDiana mooreJohnf crowleyBradley campbellTahseen mozaffarDepartment of neurologyExchange commissionGlobenewswire incAmicus therapeutics incMaltase deficiency associationTeam amicuGlobal corporate communicationsAmicus therapeutics